NASDAQ: SQFT
Presidio Property Trust, Inc.CIK 0001080657 · SIC 6798 · Real Estate Investment Trusts
Micro
Revenue $17M
Assets $107M
as of Sep 4, 2026
Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (NTSK 10-Q) is open in full — no account needed.
8-K
Filed Sep 2, 2026
· Period ending Sep 2, 2026
Summary not yet generated.
424B3
Filed Sep 2, 2026
Summary not yet generated.
Partner
Trade SQFT commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
8-K
Filed Aug 24, 2026
· Period ending Aug 24, 2026
Summary not yet generated.
10-Q
Filed Aug 13, 2026
· Period ending Jun 30, 2026
Summary not yet generated.
8-K
Filed Jun 2, 2026
· Period ending Jun 2, 2026
Summary not yet generated.
8-K
Filed May 18, 2026
· Period ending May 15, 2026
Summary not yet generated.
10-Q
Filed May 15, 2026
· Period ending Mar 31, 2026
Summary not yet generated.
10-K
Filed Mar 27, 2026
· Period ending Dec 31, 2025
Summary not yet generated.
424B3
Filed Dec 18, 2025
Summary not yet generated.
424B5
Filed Oct 14, 2025
Summary not yet generated.
424B3
Filed Aug 25, 2025
Summary not yet generated.
424B5
Filed Jul 15, 2025
Summary not yet generated.
10-K
Filed Mar 31, 2025
· Period ending Dec 31, 2024
Summary not yet generated.
424B5
Filed Jun 24, 2024
Summary not yet generated.
10-K/A
Filed Apr 26, 2024
· Period ending Dec 31, 2023
Summary not yet generated.
424B4
Filed Jun 15, 2021
Summary not yet generated.
424B4
Filed Oct 8, 2020
Summary not yet generated.
10-Q/A
Filed Sep 7, 2012
· Period ending Jun 30, 2012
Summary not yet generated.
Latest financial statements
From 10-Q filed Aug 13, 2026 (period ending Jun 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.
Consolidated Statements of Operations (Unaudited)
| Description | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| Revenues: | ||||
| Rental income | 3,756,368 | 4,281,753 | 7,440,412 | 8,314,182 |
| Fees and other income | 58,707 | 96,987 | 147,463 | 189,743 |
| Total revenue | 3,815,075 | 4,378,740 | 7,587,875 | 8,503,925 |
| Costs and expenses: | ||||
| Rental operating costs | 1,258,664 | 1,462,605 | 2,803,105 | 3,075,248 |
| General and administrative | 1,341,297 | 1,223,658 | 3,015,120 | 2,885,634 |
| Depreciation and amortization | 898,710 | 1,211,691 | 1,897,679 | 2,455,796 |
| Impairment of goodwill and real estate assets | 2,978,150 | 4,317,389 | 3,502,523 | 4,344,332 |
| Total costs and expenses | 6,476,821 | 8,215,343 | 11,218,427 | 12,761,010 |
| Other income (expense): | ||||
| Interest expense mortgage notes | (1,151,932) | (1,477,870) | (3,202,006) | (2,988,341) |
| Net gain (loss) in Conduit Pharmaceuticals marketable securities (see Note 9) | 5,743 | (7,802) | 7,728 | (184,459) |
| Interest and other income, net | 5,206 | 5,206 | 10,355 | 10,354 |
| Gain on sales of real estate, net | (21,997) | 323,359 | 150,099 | 4,777,327 |
| Gain on disposition of assets and liabilities, net | — | — | 3,416,501 | — |
| Income tax (expense) benefit | (26,630) | (53,910) | (44,687) | (28,501) |
| Total other income (expense), net | (1,189,610) | (1,211,017) | 337,990 | 1,586,380 |
| Net loss | (3,851,356) | (5,047,620) | (3,292,562) | (2,670,705) |
| Less: (Income) loss attributable to noncontrolling interests | 40,230 | (228,905) | (77,655) | (340,468) |
| Net loss attributable to Presidio Property Trust, Inc. stockholders | (3,811,126) | (5,276,525) | (3,370,217) | (3,011,173) |
| Less: Series D Preferred Stock declared dividends | — | (574,096) | — | (1,153,671) |
| Less: Series D Preferred Stock undeclared dividends in arrears | (570,541) | — | (1,141,082) | — |
| Net loss attributable to Presidio Property Trust, Inc. common stockholders | (4,381,667) | (5,850,621) | (4,511,299) | (4,164,844) |
| Net loss per share attributable to Presidio Property Trust, Inc. common stockholders: | ||||
| Basic & Diluted | (3.33) | (5.13) | (3.43) | (3.42) |
| Weighted average number of common shares outstanding basic & dilutive | 1,315,656 | 1,139,437 | 1,314,912 | 1,217,332 |
Consolidated Balance Sheets
| Description | June 30, 2026 (unaudited) | December 31, 2025 |
|---|---|---|
| ASSETS | ||
| Real estate assets and lease intangibles: | ||
| Land | 13,084,921 | 16,390,250 |
| Buildings and improvements | 80,149,146 | 101,878,107 |
| Tenant improvements | 11,468,013 | 17,645,103 |
| Lease intangibles | 1,400,602 | 3,467,798 |
| Real estate assets and lease intangibles held for investment, cost | 106,102,682 | 139,381,258 |
| Accumulated depreciation and amortization | (26,883,028) | (37,536,809) |
| Real estate assets and lease intangibles held for investment, net | 79,219,654 | 101,844,449 |
| Real estate assets held for sale, net | 15,792,645 | 6,805,255 |
| Real estate assets, net | 95,012,299 | 108,649,704 |
| Other assets: | ||
| Cash, cash equivalents and restricted cash | 5,902,592 | 7,422,359 |
| Deferred leasing costs, net | 1,175,189 | 1,340,853 |
| Goodwill | 1,317,000 | 1,317,000 |
| Investment in Conduit Pharmaceuticals marketable securities (see Notes 2 & 9) | 11,628 | 3,900 |
| Deferred tax asset | 223,388 | 223,388 |
| Other assets, net (see Note 6) | 3,016,660 | 3,095,670 |
| Total other assets | 11,646,457 | 13,403,170 |
| TOTAL ASSETS (1) | 106,658,756 | 122,052,874 |
| LIABILITIES AND EQUITY | ||
| Liabilities: | ||
| Mortgage notes payable, net | 61,844,459 | 81,936,586 |
| Mortgage notes payable related to real estate assets held for sale, net | 18,297,471 | 10,137,781 |
| Mortgage notes payable, total net | 80,141,930 | 92,074,367 |
| Accounts payable and accrued liabilities | 3,286,757 | 3,302,187 |
| Accrued real estate taxes | 1,777,995 | 1,785,029 |
| Dividends payable | — | 190,220 |
| Lease liability, net | 27,317 | 40,108 |
| Below-market leases, net | 829 | 3,316 |
| Total liabilities | 85,234,828 | 97,395,227 |
| Commitments and contingencies (see Note 10) | ||
| Equity: | ||
| Series D Preferred Stock, $0.01 par value per share; 1,000,000 shares authorized; 973,736 shares issued and outstanding (liquidation preference $25.00 per share) as of June 30, 2026 and as of December 31, 2025 | 9,737 | 9,737 |
| Series A Common Stock, $0.01 par value per share, shares authorized: 100,000,000; 1,316,939 shares and 1,314,159 shares were issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 13,169 | 13,142 |
| Additional paid-in capital | 187,145,891 | 186,762,388 |
| Dividends and accumulated losses | (173,315,519) | (169,945,302) |
| Total stockholders' equity before noncontrolling interest | 13,853,278 | 16,839,965 |
| Noncontrolling interest | 7,570,650 | 7,817,682 |
| Total equity | 21,423,928 | 24,657,647 |
| TOTAL LIABILITIES AND EQUITY | 106,658,756 | 122,052,874 |
Consolidated Statements of Cash Flows (Unaudited)
| Description | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net loss | (3,292,562) | (2,670,705) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 1,897,679 | 2,455,796 |
| Stock compensation | 383,530 | 544,376 |
| Bad debt expense | 10,433 | — |
| Gain on sale of real estate assets, net | (150,099) | (4,777,327) |
| Gain on disposition of assets and liabilities, net | (3,416,501) | — |
| Net (gain) loss in Conduit Pharmaceuticals fair value marketable securities | (7,728) | 184,459 |
| Impairment of goodwill and real estate assets | 3,502,523 | 4,344,332 |
| Amortization of financing costs | 111,195 | 137,749 |
| Amortization of below-market leases | (2,487) | (2,266) |
| Straight-line rent adjustment | 5,100 | (27,948) |
| Changes in operating assets and liabilities: | ||
| Other assets | (28,165) | 36,322 |
| Accounts payable and accrued liabilities | 1,146,771 | (411,908) |
| Deferred leasing costs | (93,626) | 14,052 |
| Accrued real estate taxes | (41,224) | (839,159) |
| Net cash used in operating activities | 24,839 | (1,012,227) |
| Cash flows from investing activities: | ||
| Real estate acquisitions | — | (9,444,465) |
| Additions to buildings and tenant improvements | (459,117) | (741,071) |
| Proceeds from sale of marketable securities | — | 13,990 |
| Proceeds from sales of real estate, net | 8,749,479 | 21,544,343 |
| Net cash provided by investing activities | 8,290,362 | 11,372,797 |
| Cash flows from financing activities: | ||
| Proceeds from mortgage notes payable, net of issuance costs | — | 6,592,396 |
| Payment of debt issuance costs | — | (247,882) |
| Repayment of mortgage notes payable | (9,270,409) | (14,014,678) |
| Payment of deferred offering costs | (49,652) | — |
| Distributions to noncontrolling interests | (324,687) | (433,804) |
| Repurchase of Series A Common Stock, at cost | — | (1,526,551) |
| Repurchase of Series D Preferred Stock, at cost | — | (327,787) |
| Dividends paid to Series D Preferred Stockholders | (190,220) | (1,153,671) |
| Net cash used in financing activities | (9,834,968) | (11,111,977) |
| Net decrease in cash equivalents and restricted cash | (1,519,767) | (751,407) |
| Cash, cash equivalents and restricted cash beginning of period | 7,422,359 | 8,036,496 |
| Cash, cash equivalents and restricted cash end of period | 5,902,592 | 7,285,089 |
| Supplemental disclosure of cash flow information: | ||
| Interest paid-mortgage notes payable | 3,222,606 | 2,998,056 |
| Income taxes paid | 57,000 | 46,511 |
| Non-cash investing activities: | ||
| Paid building and tenant improvements from prior year | (361,261) | (207,847) |
| Paid deferred offering costs from prior year | 6,589 | — |
| Non-cash financing activities: | ||
| Unpaid building and tenant improvements | 281,404 | 176,307 |
| Dividends payable Series D Preferred Stock | — | 190,393 |
Amounts as printed on the EDGAR/iXBRL face. Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗